Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PHGDH | O43175 | 17/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
| ▸ | KMO | O15229 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16775820 | 0.97 | PHGDH (0.47) | PHGDHADORA2AKMO | |
| SCHEMBL16776473 | 0.87 | FGFR4 (0.42) | PHGDHADORA2ATRPV1KMO | |
| SCHEMBL16775832 | 0.86 | FAAH (0.40) | ADORA2AKMO | |
| SCHEMBL16775834 | 0.85 | MPL (0.44) | ADORA2AKMO | |
| SCHEMBL16775833 | 0.85 | ALOX15 (0.46) | KMO | |
| SCHEMBL16775835 | 0.85 | NPC1 (0.39) | PHGDHADORA2AKMO | |
| SCHEMBL17655327 | 0.85 | PHGDH (0.49) | PHGDHADORA2A | |
| SCHEMBL16776476 | 0.85 | CA2 (0.43) | PHGDHKMO | |
| SCHEMBL16775845 | 0.85 | TRPV1 (0.39) | ADORA2ATRPV1KMO | |
| SCHEMBL16775847 | 0.85 | FGFR4 (0.43) | TRPV1KMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | PHGDH 1138/4885ADORA2A 2325/4885TRPV1 3670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.